Bio Pharma Dive

FEBRUARY 15, 2024

Armed with $94 million in funding, the biotech is marrying antibody-drug conjugates with protein degraders to create a new kind of cancer medicine.

Protein 183

Protein Antibody Medicine Drugs 183

Pharmaceutical Technology

AUGUST 5, 2022

As per the prevailing prion theory, a misfolded version of a normal cell-surface protein acts as the chief infectious agent. It is ultra-rare,” says Jesús Rodriguez Requena, PhD, associate professor in the Department of Medicine at the University of Santiago de Compostela. GlobalData is the parent company of Pharmaceutical Technology.

Drugs 299

Drugs Protein Vaccine Vaccination 299

Pharmaceutical Technology

MARCH 9, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Tumour antibody serum compositions. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.

Antibody 147

Antibody Production Protein Development 147

Scienmag

DECEMBER 16, 2021

MADISON — Small, unique antibody-like proteins known as VNARs — derived from the immune systems of sharks — can prevent the virus that causes COVID-19, its variants, and related coronaviruses from infecting human cells, according to a new study published Dec.

Protein 87

Protein Antibody Medicine 87

Medical Xpress

FEBRUARY 22, 2023

Medicines that are based on mRNAs and proteins—particularly vaccines and antibodies—are time-intensive and costly to make. The challenge is in producing the necessary mRNAs and proteins in large enough amounts at low cost.

Protein 75

Protein Medicine Production Antibody 75

Pharmaceutical Technology

JANUARY 4, 2023

TST003 is a first-in-class Gremlin1 targeting humanised monoclonal antibody. In the syngeneic tumour model, the monoclonal antibody has also improved the checkpoint inhibitor’s anti-tumour activity. The Gremlin1 protein was found to promote lineage plasticity while driving castration resistance in prostate cancer.

Antibody 242

Antibody In-Vivo In-Vitro Protein 242

Pharmaceutical Technology

APRIL 13, 2023

Clinical-stage biopharmaceutical firm Alentis Therapeutics has raised $105m in a Series C financing round for advancing transformational medicines targeting the CLAUDIN-1 protein. With a silenced effector function, ALE.F02 has been designed for targeting the stiff ECM of fibrotic tissues and organs.

Medicine 130

Medicine Development Antibody Engineer 130

pharmaphorum

SEPTEMBER 30, 2020

Regeneron’s antibody cocktail seems to reduce levels of coronavirus and improve symptoms in patients, according to early test results. This first data comes from a descriptive analysis from the seamless phase 1/2/3 trial that Regeneron hopes will hurry the medicine dubbed REGN-COV2 to market.

Antibody 135

Antibody Immune Response Trials Protein 135

Pharmaceutical Technology

FEBRUARY 3, 2023

Additionally, advances in the study of broadly neutralising antibodies (bNAbs) have led to new candidates being studied in early trials. Steven Deeks, professor of medicine at the University of California, San Francisco. mRNA vaccines can be made and modified quickly compared to protein subunit vaccines, says Montefiore.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

XTalks

DECEMBER 12, 2023

Plasma medicine is a critical and specialized field within healthcare, centering on the use of human plasma for the development and administration of life-saving treatments. Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

Pharma Mirror

OCTOBER 6, 2021

The rising need for early diagnosis of chronic diseases, coupled with growing demand for drugs which work better and have fewer side effects, is largely responsible for the growth of the protein A resin market. Chromatography requires an antibody to bind to a protein A resin.

Research 130

Research Protein Antibody Manufacturing 130

pharmaphorum

MAY 30, 2022

pharmaphorum sat down with Sunil Verma, global head of oncology, medical, at AstraZeneca, to discuss three studies that were presented at the show, which demonstrate a few of the ways oncology is advancing through precision medicine and targeted therapies. That antibody-drug conjugate then docks on the cancer cell receptor.

Antibody 116

Antibody Drugs Medicine Research 116

Scienmag

MAY 23, 2021

Credit: Correspondence to – Chandra Mohan – cmohan@central.uh.edu Oncotarget published “Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens” which reported that the current study examines urine samples from 66 subjects, comprising of 31 Urology clinic controls […].

Protein 89

Protein Antibody Medicine 89

pharmaphorum

SEPTEMBER 16, 2020

Regeneron’s COVID-19 antibody cocktail has been added to the UK’s RECOVERY trial, one of the largest of its kind in the world that is testing several potential coronavirus therapies at the same time. REGN-COV2 is a combination of two monoclonal antibodies, designed to block infections of SARS-CoV-2, the virus that causes COVID-19.

Antibody 98

Antibody Trials Manufacturing Protein 98

Scienmag

JULY 23, 2021

Antibodies capable of neutralizing multiple SARS-CoV-2 strains can inform strategies for broadly protective COVID-19 booster vaccines As the SARS-CoV-2 virus that causes COVID-19 continues to evolve, immunologists and infectious diseases experts are eager to know whether new variants are resistant to the human antibodies that recognized initial versions (..)

Antibody 75

Antibody Protein Vaccination Vaccine 75

Pharmaceutical Technology

APRIL 5, 2023

Absci has collaborated with bioinformatics firm M2GEN to expedite the development of new cancer medicines. Initially, the company will use its reverse immunology technology to search the database for antibodies from patients showing strong immune responses.

Development 130

Development Bioinformatics Drugs Immune Response 130

Scienmag

MARCH 1, 2022

The SARS-CoV-2 virus is continuously evolving and structural changes to the virus may impact the efficacy of antibody therapies and vaccines.

Protein 83

Protein Vaccination Vaccine Antibody 83

XTalks

MARCH 31, 2023

BMS researchers on the mission will study the crystallization of an assortment of their biologics medicines in microgravity. By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability.

Protein 97

Protein Research Development Manufacturing 97

Scienmag

OCTOBER 23, 2020

Oncotarget recently published a novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion Credit: Correspondence to – Dario Neri – dario.neri@pharma.ethz.ch

Recombinant Antibody 53

Recombinant Antibody Protein Antibody In-Vivo 53

Pharmaceutical Technology

JUNE 24, 2022

1 variant, on 22 June, Moderna said its booster also showed a “potent” antibody response against Omicron subvariants BA.4 5, there may be enough overlap for the bivalent vaccine to offer protection against all the subvariants, says Dr Prathit Kulkarni, assistant professor of medicine in infectious diseases at Baylor College of Medicine.

Vaccination 264

Vaccination Vaccine Antibody Medicine 264

Pharmaceutical Technology

MARCH 14, 2023

Seagen discovers, develops, and commercialises transformative cancer medicines. It is a pioneer in antibody-drug conjugates (ADCs) technology. The company’s portfolio includes four approved medicines, including three ADCs, Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin), and Tivdak (tisotumab vedotin).

Antibody 130

Antibody Medicine Engineer Protein 130

Scienmag

SEPTEMBER 18, 2020

Antibody-like proteins that capture and neutralize SARS-CoV-2 Scientists have used a new high-speed, in vitro selection method to isolate 9 antibody-like proteins (ALPs) that bind to the SARS-CoV-2 virus – 4 of which also exhibited neutralizing activity – within 4 days, according to a new study.

Protein 53

Protein Antibody In-Vitro Scientist 53

XTalks

FEBRUARY 29, 2024

Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. My initial exposure to medicine came through bench research.

Protein 94

Protein Development Clinical Trials Clinical Trials 94

Scienmag

APRIL 13, 2022

A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I human clinical trials to treat COVID-19.

Antibody 88

Antibody Protein Clinical Trials Clinical Trials 88

pharmaphorum

MAY 12, 2021

UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in on the action. . The post Lilly buys into MiNA’s protein-boosting RNA tech in $1.25bn deal appeared first on.

RNA 75

RNA Protein Drugs Pharma Companies 75

Scienmag

APRIL 9, 2021

The structural revelation could have implications as a therapeutic target in all SARS-CoV-2 variants Credit: Kelly Lab/Penn State A tiny protein of SARS-CoV-2, the coronavirus that gives rise to COVID-19, may have big implications for future treatments, according to a team of Penn State researchers.

Antibody 93

Antibody Protein Scientist Research 93

Pharmaceutical Technology

APRIL 20, 2023

Biopharmaceutical company Abdera Therapeutics has raised $142m in combined Series A and B financing to engineer and advance antibody-based radiopharmaceuticals to treat cancer. The company’s lead programme is aimed at delta-like ligand 3 (DLL3), which is a protein in the Notch pathway.

Antibody 130

Antibody Engineer Protein Drugs 130

Pharmaceutical Technology

JULY 5, 2022

Researchers at the UNC School of Medicine have discovered that hepatitis A virus (HAV) replication needs particular interactions between the human protein ZCCHC14 and TENT4 poly(A) polymerases, a group of enzymes. In addition, the scientists later found that the HAV needs TENT4A/B for its replication.

Protein 130

Protein RNA Genome Genomics 130

XTalks

JANUARY 6, 2021

Researchers at the National Institutes of Health (NIH) in the US have isolated small antibodies called “nanobodies” from a llama named Cormac that can block the SARS-CoV-2 coronavirus. Nanobodies are about a quarter of the size, and approximately one tenth of the weight, of a typical human antibody.

Antibody 105

Antibody Protein Bacteria In-Vitro 105

BioPharma Reporter

OCTOBER 24, 2022

AbbVie will acquire DJS Antibodies Ltd, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins.

Antibody 45

Antibody Protein Medicine Development 45

Pharmaceutical Technology

FEBRUARY 7, 2023

The BLA covers all indications which are covered by Prolia (denosumab) and Xgeva (denosumab) reference medicines. The human monoclonal antibody denosumab has been designed to bind to osteoclasts activator, RANKL protein. It decreases the osteoclast’s production and activity by attaching to and inhibiting RANKL.

Packaging 130

Packaging Packaging Medicine Licensing 130

pharmaphorum

AUGUST 12, 2021

A single dose of a monoclonal antibody developed by scientists at the US National Institutes of Health (NIH) has provided protection for people exposed to malaria parasites for up to nine months. The post More malaria hope as antibody protects against infection appeared first on.

Antibody 64

Antibody Vaccination Vaccine Allergies 64

Scienmag

FEBRUARY 18, 2021

A new protein is developed to bring the tumor cells and cells of the immune system together and effectively kill tumor cells Credit: Cancer Biology & Medicine Several treatments for cancer have been devised by science, but unfortunately none of them are completely efficient or foolproof.

Antibody 69

Antibody Protein Medicine Development 69

Pharmaceutical Technology

NOVEMBER 13, 2022

In the trial, the safety profile of Imjudo plus Imfinzi and chemotherapy combination treatment was in line with each medicine’s known profiles without any new safety signals detected. Imjudo (tremelimumab) is also a mAb that acts on the cytotoxic T-lymphocyte-associated protein 4’s (CTLA-4) activity.

Protein 130

Protein FDA Approval Antibody Trials 130

Scienmag

JULY 6, 2021

Studies reveal unprecedented mechanism behind loss of antibody neutralization against this pandemic coronavirus variant of concern Credit: Young-Jun Park, UW Department of Biochemistry Three mutations in the Epsilon coronavirus spike protein dampen the neutralizing potency of antibodies induced by current vaccines or past COVID infections.

Antibody 98

Antibody Protein Vaccine Vaccination 98

Pharmaceutical Technology

FEBRUARY 1, 2023

Since the FDA approved AstraZeneca’s monoclonal antibody therapy Synagis (palivizumab) 25 years ago, drug development successes for RSV have been few and far between. In 2013, this changed when an NIH lab reported the structure of the RSV protein, leading to the exploration of the RSV structure in ways that were not previously possible.

Vaccination 162

Vaccination Vaccine Antibody Development 162

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162